Latest Quote @ Sun May 5 03:03:13 (15 min delayed)
Last Day's Data
InterMune, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies in pulmonology and hepatology. The company markets various products, including Actimmune (interferon gamma-1b) for the treatment of severe osteopetrosis, and chronic granulomatous disease; Infergen (consensus interferon alfacon-1) for the treatment of patients with compensated liver disease with chronic hepatitis C virus infections; and Amphotec (amphotericin B cholesteryl sulfate complex for injection) for the treatment of invasive aspergillosis. In pulmonology area, InterMune develops Actimmune, a second phase III clinical trial, which is used for the treatment of patients with idiopathic pulmonary fibrosis; and interferon gamma-1b under the name Imukin. In hepatology area, it is developing once-daily Infergen in combination with ribavirin therapy for the treatment of patients suffering from chronic HCV infections; Infergen in combination with Actimmune, which is in Phase IIb clinical trial for the treatment of hepatitis C nonresponders; and PEG-Alfacon-1 that completed phase I clinical trial for the treatment of chronic HCV infections. In addition, the company evaluates Actimmune in patients with ovarian cancer in a Phase III trial. InterMune has collaboration and licensing agreements with Boehringer Ingelheim International GmbH; Maxygen Holdings, Ltd.; and Array BioPharma, Inc. The company was incorporated in 1998 and is headquartered in Brisbane, California.